Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?
Cooley M&A
JANUARY 22, 2025
This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. The FTC nevertheless has remained focused on the life sciences/medical device sector in other parts of its enforcement efforts. Similarly, Novo Holdings $16.5
Let's personalize your content